? This is an application for the renewal of our Drug Abuse Training Program at Temple University that is currently in its 15th year. The purpose of the Drug Abuse Training Program is to provide a comprehensive training experience for pre- and postdoctoral fellows in the area of drug abuse and addiction. Our program is multidisciplinary in nature with participating faculty residing in the Departments of Pharmacology, Microbiology, Biochemistry, Psychology, Pharmaceutics, and Biology. Our investigators have research interests in the area of opioids, psychostimulants, cannabinoids, nicotine, and alcohol, and are investigating these agents on measures of analgesia, immune function, reinforcement, temperature regulation, learning, conditioning, and HIV infectivity. The laboratory approaches used are state-of-the-art and range from molecular biology to behavior and include both human and animal research. Historically, the strengths of our faculty have resided in the areas of opioid pharmacology and neuroimmunopharmacology and these strengths continue, with our researchers making substantial contributions to these fields. More recently, we have expanded to include strong programs in the pharmacology of psychostimulants, cannabinoids, and nicotine. Our predoctoral trainees are exposed to a rigorous program of both didactic and laboratory experiences. Postdoctoral trainees concentrate on research during their training but are required to participate in courses related to the field of drug abuse. All trainees will receive instruction in pharmacology, immunology, behavior, biostatistics, and the responsible conduct of research. The Drug Abuse Training Program also involves a variety of career development activities for all of our trainees, such as manuscript writing, oral communication skills, grant preparation, teaching experience, and attendance at national scientific meetings. The goal of our program is to facilitate our trainees to become productive and independent researchers highly knowledgeable in research areas impacting drug abuse and addiction. This program provides a strongly interactive, dynamic, and supportive environment for trainees to develop into outstanding researchers. This is the only training program in the Philadelphia area with this expertise and mission. ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
5T32DA007237-19
Application #
7258905
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Avila, Albert
Project Start
1988-09-01
Project End
2009-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
19
Fiscal Year
2007
Total Cost
$493,667
Indirect Cost
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
057123192
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Ward, Sara Jane; Castelli, Francesca; Reichenbach, Zachary W et al. (2018) Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci 195:1-5
Oliver, Chicora F; Simmons, Steven J; Nayak, Sunil U et al. (2018) Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats. Drug Alcohol Depend 186:75-79
Gentile, Taylor A; Simmons, Steven J; Barker, David J et al. (2018) Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addict Biol 23:247-255
Hicks, Callum; Huang, Peng; Ramos, Linnet et al. (2018) Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. ACS Chem Neurosci 9:1327-1337
Wickens, Megan M; Bangasser, Debra A; Briand, Lisa A (2018) Sex Differences in Psychiatric Disease: A Focus on the Glutamate System. Front Mol Neurosci 11:197
Andrews, Allison M; Lutton, Evan M; Cannella, Lee A et al. (2018) Characterization of human fetal brain endothelial cells reveals barrier properties suitable for in vitro modeling of the BBB with syngenic co-cultures. J Cereb Blood Flow Metab 38:888-903
Simmons, Steven J; Gregg, Ryan A; Tran, Fionya H et al. (2018) Comparing rewarding and reinforcing properties between 'bath salt' 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats. Addict Biol 23:102-110
Hill, Jeremy D; Zuluaga-Ramirez, Viviana; Gajghate, Sachin et al. (2018) Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol :
Hicks, Callum; Gregg, Ryan A; Nayak, Sunil U et al. (2017) Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG). Psychopharmacology (Berl) 234:1671-1681
Philogene-Khalid, Helene L; Hicks, Callum; Reitz, Allen B et al. (2017) Synthetic cathinones and stereochemistry: S enantiomer of mephedrone reduces anxiety- and depressant-like effects in cocaine- or MDPV-abstinent rats. Drug Alcohol Depend 178:119-125

Showing the most recent 10 out of 200 publications